5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
DRUG

Regorafenib (BAY 73-4506)

Regorafenib will be administered a starting dose of 80 mg per day with weekly 40 mg per day increases to a maximum of 120 mg per day for 3 weeks on / 1 week off continued until disease progression or unacceptable toxic effects occurred or consent was withdrawn, up to 12 cycles of treatment.

DRUG

5FU/LV

5FU/LV administered as (LV \[400 mg/m² IV over 120 minutes\], followed by 5FU \[400 mg/m² IV bolus then 2400 mg/m² IV infusion over 46 hours\] in 2-week cycles)

DRUG

Bevacizumab

Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered intravenously on days 1 and 15.

DRUG

Trifluridine-tipiracil

FTD-TPI, administered orally, BID, at a starting dose of 35 mg/m2 of body-surface area, on days 1 through 5 and on days 8 through 12 every 28 days.

Trial Locations (1)

77030

RECRUITING

Houston Methodist Neal Cancer Center, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER